EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low‐Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag

Jiaojiao Yuan, Junjie Cao, Peipei Ye, Tiantian Wang, Dong Chen, Shuangyue Li, Renzhi Pei, Juntao Zhang, Ying Lu iD

Cancer Medicine · 2026-03 · 15 (3)

DOI: 10.1002/cam4.71636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 15.03.2026. Verfasst von Jiaojiao Yuan und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated People's Hospital of Ningbo University, Zhejiang, China. Hauptthemen laut MEDLINE: Benzoates, Hematopoietic Stem Cell Transplantation, Hydrazines, Decitabine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningbo Medical Science and Technology Project, Ningbo Clinical Research Center for Ophthalmology, Ningbo University Teaching Research Project 2025.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Primary poor graft function (PGF) is a common and serious complication after haploidentical hematopoietic stem cell transplantation (haplo‐HSCT). This study retrospectively evaluates the efficacy and safety of a novel combination therapy consisting of low‐dose decitabine, donor lymphocyte infusion (DLI), and eltrombopag for the treatment of primary PGF subsequent to haplo‐HSCT.

Methods

In this analysis of ten patients, decitabine was administered at a dose of 7 mg/m 2 /day for three consecutive days, followed by DLI on the fifth day and eltrombopag, which was started at 50 mg/day and titrated up to 150 mg. The primary endpoints of the study encompassed hematologic recovery.

Results

Nine patients (90%) achieved a complete response with normalized blood counts, while one patient (10%) showed a partial response with transfusion independence. Adverse events included manageable graft‐versus‐host disease (GVHD) in four patients.

Conclusion

These findings indicate that this triple therapy represents a promising approach for the management of primary PGF following haplo‐HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoatesHematopoietic Stem Cell TransplantationHydrazinesDecitabinePyrazolesLymphocyte TransfusionHumansFemaleMaleGraft vs Host DiseaseAdultMiddle AgedTreatment OutcomeRetrospective StudiesTransplantation, HaploidenticalYoung Adult

Substanzen

eltrombopagBenzoatesHydrazinesDecitabinePyrazoles

Autor:innen und Institutionen

  • The Affiliated People's Hospital of Ningbo University, Zhejiang, China.
  • Institute of Hematology, Ningbo University, Zhejiang, China.

ORCID-Profile: Ying Lu

Förderung

  • Ningbo Medical Science and Technology Project
  • Ningbo Clinical Research Center for Ophthalmology
  • Ningbo University Teaching Research Project 2025
  • Yinzhou District Agricultural and Social Development Science and Technology Project
  • Zhejiang Province Medical and Health Science and Technology Project

Zitieren

APA

Yuan, J., Cao, J., Ye, P., Wang, T., Chen, D., Li, S., Pei, R., Zhang, J., & Lu, Y. (2026). Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low‐Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag. Cancer Medicine, 15(3). https://doi.org/10.1002/cam4.71636

Vancouver

Yuan J, Cao J, Ye P, Wang T, Chen D, Li S, et al. Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low‐Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag. Cancer Medicine. 2026;15(3). doi:10.1002/cam4.71636

BibTeX
@article{Yuan2026,
  author = {Yuan, Jiaojiao and Cao, Junjie and Ye, Peipei and Wang, Tiantian and Chen, Dong and Li, Shuangyue and Pei, Renzhi and Zhang, Juntao and Lu, Ying},
  title = {Successful Treatment of Primary Poor Graft Function After Haploidentical Hematopoietic Stem Cell Transplantation With Low‐Dose Decitabine Followed by Donor Lymphocyte Infusion and Eltrombopag},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cam4.71636}
}
Kostenlos starten →